Inflammatory Markers and Physical Performance in Older Persons: The InCHIANTI Study

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 59, Issue 3, 2004, Pages 242-248

  Cesari, Matteo ^a,f   Penninx, Brenda W J H ^a   Pahor, Marco ^a   Lauretani, Fulvio ^b   Corsi, Anna Maria ^b   Williams, G Rhys ^c   Guralnik, Jack M ^d   Ferrucci, Luigi ^b,e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CNR   (Italy)

^c BRISTOL MYERS SQUIBB   (United States)

^d Laboratory of Membrane Biochemistry and Biophysics   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; STATINE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANGINA PECTORIS; ARTICLE; BALANCE DISORDER; CANCER; CHAIR; CHAIR STAND TEST; CHRONIC INFLAMMATION; CLINICAL STUDY; CORRELATION ANALYSIS; COVARIANCE; DIABETES MELLITUS; DISABILITY; DISEASE MARKER; FEMALE; HAND GRIP; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INCHIANTI STUDY; INFLAMMATION; ITALY; LINEAR REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PHYSICAL PERFORMANCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SCREENING TEST; STANDING BALANCE TEST; VALIDATION PROCESS; WALKING SPEED;

ANGINA;

EID: 1642316427     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/59.3.m242     Document Type: Article

References (45)

1. Larsson L, Ramamurthy B. Aging-related changes in skeletal muscle. Mechanisms and interventions. Drugs Aging. 2000;17:303-316.
2. Rosenberg IH, Miller JW. Nutritional factors in physical and cognitive functions of elderly people. Am J Clin Nutr. 1992;55[6 Suppl]:1237S-1243S.
3. Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a predictor of old age disability. JAMA. 1999;281:558-560.
4. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol Med Sci. 1994;49:M85-M94.
5. Al Snih S, Markides KS, Ray L, Ostir GV, Goodwin JS. Handgrip strength and mortality in older Mexican Americans. J Am Geriatr Soc. 2002;50:1250-1256.
6. Kuller LH. Serum levels of IL-6 and development of disability in older persons. J Am Geriatr Soc. 1999;47:755-756.
7. Taaffe DR, Harris TB, Ferrucci L, Rowe JW, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur Studies of Successful Aging. J Gerontol Med Sci. 2000;55A:M709-M715.
8. Reuben DB, Cheh AI, Harris TB, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50:638-644.
9. Van Stick J. Interleukin-6: an overview. Ann Rev Immunol. 1990;8:253-278.
10. Beutler M, Milsark IW, Cerami A. Cachetin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;135:3972-3977.
11. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
12. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
13. Skoog T, Dichtl W, Boquist S, et al. Plasma tumor necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Health J. 2002;23:376-383.
14. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the Health ABC study. J Gerontol Med Sci. 2002;57A:M326-M332.
15. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol. 2000;20:1057-1060.
16. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47:639-646.
17. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50:1268-1271.
18. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002;13:561-568.
19. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retrov. 1997;13:1047-1054.
20. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
21. Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169-1176.
22. Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta. 2002;1592:251-263.
23. Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM, for the InCHIANTI Group. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc. 2000;48:1618-1625.
24. Onder G, Penninx BWJH, Lapuerta P, et al. Change in physical performance over time in older women: the Women's Health and Aging Study. J Gerontol Med Sci. 2002;57A:M289-M293.
25. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace R, Carbonin PU. Drug data coding and analysis in epidemiologic studies. Eur J Clin Epidemiol. 1994;10:405-411.
26. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153:242-250.
27. Cohen HJ, Pieper CF, Harris TB, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol Med Sci. 1997;52A:M201-M208.
28. Feakes R, Sawcer S, Broadley S, et al. Interleukin 1 receptor antagonist (IL-1RA) in multiple sclerosis. J Neuroimmunol. 2000;105:96-101.
29. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest. 1991;88:1445-1451.
30. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627-1652.
31. Berger P, McConnell JP, Nunn M, et al. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine. 2002;17:171-174.
32. Schiff MH. Role of interleukin-1 and interleukin-1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis. 2000;59:i103-i108.
33. Pellicane JV, DeMaria EJ, Abd-Elfattah A, Reines HD, Vannice JL, Carson KW. Interleukin-1 receptor antagonist improves survival and preserves organ adenosine-5′-triphosphate after hemorrhagic shock. Surgery. 1993;114:278-283.
34. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokines receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 1999;33:1935-1942.
35. Porsch-Oezcueruemez M, Kunz D, Kloer HU, Luley C. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol. 1999;34:1995-2001.
36. Tracy RP, Psaty B, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
37. Juhan-Vague I, Thompson S, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb. 1993;13:1865-1873.
38. Samaras K, Campbell L. The non-genetic determinants of central adiposity. Int J Obes Relat Metab Disord. 1997;21:839-845.
39. Mayer-Davis EJ, D'Agostino RJ, Karter A, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA. 1998;279:669-674.
40. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683-693.
41. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumor necrosis factor-α induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem. 1993;125:11-18.
42. Hoshino E, Pichard C, Greenwood CE, et al. body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol. 1991;260:E27-E36.
43. Charters Y, Grimble RF. Effect of recombinant human tumor necrosis factor α on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J. 1989;258:493-497.
44. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body dell mass in chronic inflammation. J Clin Invest. 1994;93:2379-2386.
45. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824.